Self-assembling peptides are attracting growing interest in the fast-evolving fields of regenerative medicine and surgery. Among them, RADA16—the active component of the medical device PuraStat®—stands out as a promising solution for surgical hemostasis and tissue repair. A review by Sankar, O’Neill, and Bagot d’Arc highlights the current applications and future perspectives of this next-generation biomaterial.
What Is the Self-Assembling Peptide RADA16?
RADA16 is a synthetic peptide formulated as a viscous solution under acidic conditions. In this environment, the peptides spontaneously self-assemble into β-sheet nanofibers. When exposed to the physiological pH of biological fluids such as blood, interstitial fluid, or lymph, these nanofibers physically crosslink within seconds, forming a stable, transparent, three-dimensional hydrogel matrix.
The structure of the RADA16 hydrogel closely resembles the natural architecture of native extracellular matrices. These properties make RADA16 formulations ideal as topical hemostatic agents to control bleeding during surgery and to prevent postoperative re-bleeding.
Another advantage is safety: being fully synthetic, RADA16 avoids the risks of microbiological contamination and immune reactions often associated with animal-, plant-, or mineral-based hemostatic agents. Its three-dimensional nanofiber structure supports biocompatibility, natural resorption, and tissue regeneration.
Looking ahead, the unique properties of self-assembling peptides like RADA16 may allow them to be used as carriers for controlled drug delivery and as scaffolds in regenerative medicine.
Source: ResearchGate
PuraStat®: A Clinically Validated Application in Surgical Hemostasis
PuraStat®, a Class III medical device based on RADA16, is already used in multiple surgical specialties for intraoperative bleeding control:
- Cardiovascular surgery – rapid control of diffuse bleeding on fragile tissues
- Gastroenterology – prevention and control of bleeding after polypectomy or mucosal dissection
- ENT (Ear, Nose, Throat) surgery – local hemostasis during sinus or pharyngeal procedures
Reference: Clinical Use of the Self-Assembling Peptide RADA16 – PubMed Central
Reducing Postoperative Adhesions: Evidence from Preclinical Studies
An in vivo rabbit study (cecal wall model) demonstrated that applying PuraStat® significantly reduced postoperative adhesions compared with controls:
- −76% in global adhesion score
- −79% in adhesion surface
- −72% in adhesion durability
These results, published on Frontiers in Surgery, confirm the potential of RADA16 in reducing adhesion formation in abdominal surgery.
Wound Healing: Promising Preclinical Data
RADA16-based self-assembling peptides, including modified functional motifs, significantly accelerated wound closure at days 7 and 14. The effect was observed in both diabetic and non-diabetic animal models. These findings suggest a strong potential for accelerating cutaneous wound healing in future human applications.
Source: PubMed Central
Why Do Self-Assembling Peptides Attract So Much Interest?
The enthusiasm surrounding RADA16 and related biomaterials is linked to several clear advantages:
- Biocompatibility and full resorption – no residual toxicity
- Ease of use – transparent gel, easily applied to difficult-to-reach areas (MDPI, Nature)
- Versatility – potential applications across gastrointestinal, cardiovascular, ENT, and uro-gynecological surgery
In Summary: A High-Potential Biomaterial
RADA16, through its clinical application in PuraStat®, represents a discreet yet transformative innovation in surgery and wound healing. Its validated role in surgical hemostasis, its promising outcomes in adhesion prevention and wound healing, and its technological adaptability position it as a strategic biomaterial for healthcare professionals and clinical researchers.
For clinical trial sponsors, medical device manufacturers, and innovators in surgical practice, maintaining active surveillance on self-assembling peptides is crucial. These biomaterials may well redefine the standards of safety, efficiency, and recovery in tomorrow’s operating rooms.
See article on the same subject : Self-assembling peptides: a new generation of medical devices for surgical haemostasis
